TPH1
Tryptophan 5-hydroxylase 1
As of the edition of 20 October 2026, TPH1 (tryptophan 5-hydroxylase 1, UniProt P17752) has 4 drugs tested at it and 5 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P17752
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 21
- Disease areas
- Chemically induced; Cancer; Digestive system; Lungs and airways; Heart and blood vessels; Hormones; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 34
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Telotristat ethyl | Marketed | Phase 3 | Ends 2031 |
| Rodatristat ethyl | Stopped | Phase 2 | none listed |
| LX1031 | Went quiet | Phase 2 | none listed |
| Telotristat | Stopped | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Altavant Sciences | Route A |
| TerSera Therapeutics | Route B |
| Serb | Route B |
The other 2 companies at TPH1
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at TPH1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.